97 related articles for article (PubMed ID: 11249671)
1. Technology evaluation: CRIB (CNTF delivery) CytoTherapeutics Inc.
Abicht A; Lochmüller H
Curr Opin Mol Ther; 1999 Oct; 1(5):645-50. PubMed ID: 11249671
[TBL] [Abstract][Full Text] [Related]
2. Update on immunoisolation cell therapy for CNS diseases.
Emerich DF; Salzberg HC
Cell Transplant; 2001; 10(1):3-24. PubMed ID: 11294469
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF.
Bachoud-Lévi AC; Déglon N; Nguyen JP; Bloch J; Bourdet C; Winkel L; Rémy P; Goddard M; Lefaucheur JP; Brugières P; Baudic S; Cesaro P; Peschanski M; Aebischer P
Hum Gene Ther; 2000 Aug; 11(12):1723-9. PubMed ID: 10954906
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.
Aebischer P; Pochon NA; Heyd B; Deglon N; Joseph JM; Zurn AD; Baetge EE; Hammang JP; Goddard M; Lysaght M; Kaplan F; Kato AC; Schluep M; Hirt L; Regli F; Porchet F; De Tribolet N
Hum Gene Ther; 1996 May; 7(7):851-60. PubMed ID: 8860837
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease.
de Almeida LP; Zala D; Aebischer P; Déglon N
Neurobiol Dis; 2001 Jun; 8(3):433-46. PubMed ID: 11442352
[TBL] [Abstract][Full Text] [Related]
6. Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa.
Emerich DF; Thanos CG
Curr Gene Ther; 2006 Feb; 6(1):147-59. PubMed ID: 16475952
[TBL] [Abstract][Full Text] [Related]
7. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration.
Schlichtenbrede FC; MacNeil A; Bainbridge JW; Tschernutter M; Thrasher AJ; Smith AJ; Ali RR
Gene Ther; 2003 Mar; 10(6):523-7. PubMed ID: 12621456
[TBL] [Abstract][Full Text] [Related]
8. CRIB (NGF delivery) Cyto Therapeutics Inc.
Cockett MI
IDrugs; 1998 Jul; 1(3):362-7. PubMed ID: 18465562
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in immunoisolated cell therapy.
Lysaght MJ; Frydel B; Gentile F; Emerich D; Winn S
J Cell Biochem; 1994 Oct; 56(2):196-203. PubMed ID: 7829581
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.
Aebischer P; Schluep M; Déglon N; Joseph JM; Hirt L; Heyd B; Goddard M; Hammang JP; Zurn AD; Kato AC; Regli F; Baetge EE
Nat Med; 1996 Jun; 2(6):696-9. PubMed ID: 8640564
[TBL] [Abstract][Full Text] [Related]
11. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis.
Al-Chalabi A; Scheffler MD; Smith BN; Parton MJ; Cudkowicz ME; Andersen PM; Hayden DL; Hansen VK; Turner MR; Shaw CE; Leigh PN; Brown RH
Ann Neurol; 2003 Jul; 54(1):130-4. PubMed ID: 12838531
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.
Bloch J; Bachoud-Lévi AC; Déglon N; Lefaucheur JP; Winkel L; Palfi S; Nguyen JP; Bourdet C; Gaura V; Remy P; Brugières P; Boisse MF; Baudic S; Cesaro P; Hantraye P; Aebischer P; Peschanski M
Hum Gene Ther; 2004 Oct; 15(10):968-75. PubMed ID: 15585112
[TBL] [Abstract][Full Text] [Related]
13. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?
Iłzecka J
Curr Opin Investig Drugs; 2006 Jan; 7(1):54-9. PubMed ID: 16425672
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells.
Zurn AD; Henry H; Schluep M; Aubert V; Winkel L; Eilers B; Bachmann C; Aebischer P
Cell Transplant; 2000; 9(4):471-84. PubMed ID: 11038064
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vectors for the treatment of neurodegenerative diseases.
Martin-Rendon E; Azzouz M; Mazarakis ND
Curr Opin Mol Ther; 2001 Oct; 3(5):476-81. PubMed ID: 11699892
[TBL] [Abstract][Full Text] [Related]
16. Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia.
Rinsch C; Quinodoz P; Pittet B; Alizadeh N; Baetens D; Montandon D; Aebischer P; Pepper MS
Gene Ther; 2001 Apr; 8(7):523-33. PubMed ID: 11319619
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological, cell, and gene therapy strategies to promote spinal cord regeneration.
Blits B; Boer GJ; Verhaagen J
Cell Transplant; 2002; 11(6):593-613. PubMed ID: 12428749
[TBL] [Abstract][Full Text] [Related]
18. Increased serum CNTF level in patients with amyotrophic lateral sclerosis.
Iłzecka J
Eur Cytokine Netw; 2003; 14(3):192-4. PubMed ID: 14656696
[TBL] [Abstract][Full Text] [Related]
19. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa.
Tao W; Wen R; Goddard MB; Sherman SD; O'Rourke PJ; Stabila PF; Bell WJ; Dean BJ; Kauper KA; Budz VA; Tsiaras WG; Acland GM; Pearce-Kelling S; Laties AM; Aguirre GD
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3292-8. PubMed ID: 12356837
[TBL] [Abstract][Full Text] [Related]
20. Ciliary neurotrophic factor null alleles are not a risk factor for Charcot-Marie-Tooth disease, hereditary neuropathy with pressure palsies and amyotrophic lateral sclerosis.
Van Vught PW; Van Wijk J; Bradley TE; Plasmans D; Jakobs ME; Veldink JH; de Jong JM; Van den Berg LH; Baas F
Neuromuscul Disord; 2007 Dec; 17(11-12):964-7. PubMed ID: 17651970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
